Therapy News and Research

RSS

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

MedNet Solutions, a global life sciences technology solutions company specializing in clinical study management systems, is pleased to announce that Allos Therapeutics' new international disease-specific registry for patients with peripheral T-cell lymphoma (PTCL) has enrolled its first study participant.

11 Feb 2010

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

Principio Inc., a privately held emerging company developing novel molecular imaging agents and therapeutic radiopharmaceuticals for the treatment of cancer, today announced that the Company has obtained an exclusive license to several technologies developed at Johns Hopkins Sidney Kimmel Comprehensive Cancer Center.

11 Feb 2010

MUHC commences clinical trial of Exsulin for type 1 diabetes

A clinical trial of Exsulin, an innovative new treatment that targets the underlying cause of type 1 diabetes, has begun at the McGill University Health Centre (MUHC). Under the direction of Dr. George Tsoukas of the MUHC and the McGill University Faculty of Medicine, the study will assess the effectiveness of Exsulin.

11 Feb 2010

CINJ researchers develop new vaccine strategy for pancreatic cancer

More than 42,500 people in the United States were diagnosed with pancreatic cancer last year and nearly 35,200 died from the disease, according to The American Cancer Society.

11 Feb 2010

Cardiology 2010 conference focuses on current treatments for children with heart disease

An international group of over 900 medical experts gathers today to discuss the most current treatments for children with heart disease. Affecting about 8 in every 1,000 children, congenital (present at birth) heart disease is the most common birth defect. In its severe forms, it is also the leading cause of death from birth defects in infants.

10 Feb 2010

$TZD drug may increase fracture risk in older women$

TZD drug may increase fracture risk in older women

A Henry Ford Hospital study finds women with type 2 diabetes who take a commonly prescribed class of medications to treat insulin resistance may be at a higher risk for developing bone fractures.

10 Feb 2010

Boston Scientific reports fourth quarter and full year 2009 results

Boston Scientific Corporation today announced financial results for the fourth quarter and full year ended December 31, 2009, as well as guidance for net sales and earnings per share (EPS) for the first quarter and full year 2010.

10 Feb 2010

Trimel BioPharma Holdings updates business developments

Trimel BioPharma Holdings Inc. is today providing an update on a number of operational items that have contributed significantly to advancing the Company and achieving its initial objectives.

10 Feb 2010

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, owing to increasing competition from other biologic agents, Amgen/Pfizer/Takeda's Enbrel (etanercept)—the leading therapy in the psoriasis drug market in 2008—will account for less than one-fifth of sales in the overall market in 2018. In 2008, Enbrel garnered half of the psoriasis drug market share in the United States, France, Germany, Italy, Spain, the United Kingdom and Japan.

10 Feb 2010

Study shows more women die of heart disease each year than men

Cardiovascular disease (commonly referred to as heart disease) is the leading cause of death for women worldwide. Almost every minute, a woman in the U.S. dies from heart disease. Despite the prevalence of heart disease in women, a 2005 American Heart Association study showed that 92% of primary care physicians and 83% of cardiologists were not aware of the fact that more women than men die of heart disease each year.

10 Feb 2010

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Genzyme Corp. and Isis Pharmaceuticals Inc. today announced that the phase 3 study of mipomersen in patients with heterozygous familial hypercholesterolemia (heFH) met its primary endpoint with a highly statistically significant 28 percent reduction in LDL-cholesterol after 26 weeks of treatment, compared with an increase of 5 percent for placebo.

10 Feb 2010

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Naurex Inc., a clinical stage company developing innovative treatments for depression and other CNS disorders based on its novel glycine site functional partial agonist (GFPA) NMDA receptor modulators, today reported positive top-line results from its Phase I clinical trial of lead compound GLYX-13.

10 Feb 2010

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

Bioniche Life Sciences Inc., a research-based, technology-driven Canadian biopharmaceutical company, today announced financial results for its Fiscal 2010 second quarter, ended December 31, 2009.

10 Feb 2010

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

A new study reveals that multiple sclerosis (MS) patients enrolled in a seven-month disease therapy management (DTM) program show greater adherence to injectable MS medications and treatment persistence than patients who receive injectable MS medications through a community pharmacy.

10 Feb 2010

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Provectus Pharmaceuticals, Inc., a development-stage oncology and dermatology biopharmaceutical company, announces the publication of an article, entitled “A novel treatment for metastatic melanoma with intralesional rose bengal and radiotherapy: a case series," authored by Dr. Matthew C. Foote, Dr. Bryan H. Burmeister, Janine Thomas, and Dr. B. Mark Smithers, in the current issue of the peer-reviewed journal, Melanoma Research (20(1):48-51, February 2010).

10 Feb 2010

Age-related gaps in care and outcomes for stroke patients are diminishing in hospitals

Age-related gaps in care and outcomes for stroke patients are diminishing as hospitals improve adherence to evidence-based treatments of the American Heart Association/American Stroke Association's Get With The Guidelines–Stroke initiative, according to a new study in Circulation: Journal of the American Heart Association.

10 Feb 2010

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Clarient, Inc., a premier technology and services resource for pathologists, oncologists and the pharmaceutical industry, today announced the commercial launch of a new lung cancer test, Clarient Insight® Dx Pulmotype® Test, that helps physicians classify specific types of lung cancer to identify which therapies may be most effective.

10 Feb 2010

Pivotal Research to study investigational drug for menstrual cramps

A leading clinical research center in Peoria has joined an international research program to study an investigational drug designed as a possible treatment for painful menstrual cramps, or dysmenorrhea, a condition that affects between 45 and 90 percent of women of childbearing age in the United States.

10 Feb 2010

New research suggests closantel drug may be useful in combating river blindness

Scientists at The Scripps Research Institute have discovered a potential new use for the drug closantel, currently the standard treatment for sheep and cattle infected with liver fluke. The new research suggests that the drug may be useful in combating river blindness, a tropical disease that is the world's second leading infectious cause of blindness for humans.

10 Feb 2010

Your Hormones, Your Health!: Free health seminar

Dr. Gino Tutera, an innovative physician who developed cutting-edge techniques in the field of hormone replacement therapy, is hosting a seminar entitled: Your Hormones, Your Health!

10 Feb 2010

Therapy News and Research

Allos Therapeutics' disease-specific registry for patients with PTCL enrolls first study participant

Principio, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center sign technology licensing agreement

MUHC commences clinical trial of Exsulin for type 1 diabetes

CINJ researchers develop new vaccine strategy for pancreatic cancer

Cardiology 2010 conference focuses on current treatments for children with heart disease

TZD drug may increase fracture risk in older women

Boston Scientific reports fourth quarter and full year 2009 results

Trimel BioPharma Holdings updates business developments

Psoriasis drug Enbrel to account for less than one-fifth of sales in 2018 overall market

Study shows more women die of heart disease each year than men

Genzyme and Isis Pharmaceuticals: Phase 3 mipomersen study in heFH patients meets primary endpoint

Positive results from Naurex's Phase I clinical trial of GLYX-13 reported

Second-quarter fiscal 2010 results announced by Bioniche Life Sciences

DTM programs increase adherence to injectable medications and treatment persistence in MS patients

Provectus Pharmaceuticals publishes article on novel treatment for metastatic melanoma

Age-related gaps in care and outcomes for stroke patients are diminishing in hospitals

Clarient launches Clarient Insight Dx Pulmotype Test for lung cancer

Pivotal Research to study investigational drug for menstrual cramps

New research suggests closantel drug may be useful in combating river blindness

Your Hormones, Your Health!: Free health seminar

Industry Focus eBook - Neurology/Neuroscience - 2nd edition eBook

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Advancing Intracellular Delivery with LumiPore®

Latest News